Pitcairn Co. Has $1.24 Million Stock Holdings in AstraZeneca PLC $AZN

Pitcairn Co. decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 13.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,184 shares of the company’s stock after selling 2,611 shares during the period. Pitcairn Co.’s holdings in AstraZeneca were worth $1,242,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AZN. Cibc World Market Inc. grew its holdings in AstraZeneca by 21.5% in the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock worth $4,942,000 after purchasing an additional 11,398 shares during the period. TD Asset Management Inc boosted its position in shares of AstraZeneca by 20.0% during the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares in the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of AstraZeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after buying an additional 35,148 shares during the period. AMG National Trust Bank grew its stake in shares of AstraZeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after buying an additional 7,289 shares during the period. Finally, Oxbow Advisors LLC raised its stake in AstraZeneca by 96.2% during the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock worth $5,953,000 after buying an additional 38,043 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Citigroup initiated coverage on AstraZeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. TD Cowen restated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $194.44 on Friday. The company has a fifty day moving average price of $146.71 and a 200-day moving average price of $106.25. The firm has a market cap of $301.56 billion, a price-to-earnings ratio of 64.60, a PEG ratio of 1.59 and a beta of 0.32. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a 1 year low of $122.48 and a 1 year high of $212.71.

AstraZeneca Dividend Announcement

The firm also recently declared a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s dividend payout ratio (DPR) is 66.26%.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.